Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > The Spirit Molecule (DMT)

<< Previous

Bullboard Posts

Next >>

Comment by nodaytraderon Jan 12, 2022 1:41pm

109 Views

Post# 34309127

RE:RE:RE:RE:RE:RE:RE:The Spirit Molecule (DMT)

Perhaps I didn't explain myself very well.

I am not advocating for Ifenprodil or suggesting that the company do anything different from what they are now doing.

A stallholder knows that most of his product will attract little interest - but as long as there's a chance that somebody might be interested, he will lay it out.

There may be other products that are much more profitable but his goal is to collect maximum aggregate profit.

<< Previous

Bullboard Posts

Next >>

Thesis Gold makes high-grade discovery at Ring Zone